Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Grace Therapeutics, Inc GRCE

Healthcare
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel... see more

Recent & Breaking News (NDAQ:GRCE)

Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients (>20%) Have Completed Their 6 Month Treatment Plan

GlobeNewswire December 31, 2018

Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia

GlobeNewswire December 20, 2018

Acasti Pharma to Present at the 11th Annual LD Micro Main Event

Accesswire November 27, 2018

Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019

GlobeNewswire November 14, 2018

Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call

GlobeNewswire November 7, 2018

Acasti Pharma Announces Closing of C$27.6 Million Underwritten Public Offering of Common Shares Including the Exercise of the Over-Allotment Option

GlobeNewswire October 23, 2018

Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares

GlobeNewswire October 11, 2018

IIROC Trading Resumption - ACST

Canada NewsWire October 4, 2018

Acasti Pharma Prices C$24 Million Underwritten Offering

GlobeNewswire October 4, 2018

Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering of Common Shares

GlobeNewswire October 4, 2018

IIROC Trading Halt - ACST

Canada NewsWire October 4, 2018

The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut

Benzinga.com  October 4, 2018

26 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  October 4, 2018

10 Stocks To Watch For October 4, 2018

Benzinga.com  October 4, 2018

Acasti Pharma Announces Public Equity Offering

GlobeNewswire October 3, 2018

Acasti Pharma Announces Proposed Underwritten Public Offering of Common Shares

GlobeNewswire October 3, 2018

45 Biggest Movers From Yesterday

Benzinga.com  October 3, 2018

Mid-Afternoon Market Update: Stitch Fix Falls After Q4 Results; Pyxus International Shares Climb

Benzinga.com  October 2, 2018

38 Stocks Moving In Tuesday's Mid-Day Session

Benzinga.com  October 2, 2018

The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares

Benzinga.com  October 2, 2018